Our take
EQUASHIELD Pro is the only automated compounder that uses closed system transfer devices from start to finish, Equashield says, to keep hazardous drugs from leaking or vaporizing during compounding. It is rated at up to 70 doses an hour and is sized to fit existing pharmacy space.1
It suits oncology pharmacies that already use Equashield's closed transfer devices. Prices are not published.1,2
Scores by criterion
Pricing transparency, 2.5: Equashield publishes no prices for the Pro and offers a brochure and contact form instead.1
Product maturity, 7.0: The Pro produces a wide range of patient-specific doses and uses Equashield's dose verification system to catch drug, dose, and labeling errors.1
Deployment evidence, 6.0: Equashield sells on five continents and runs a knowledge base for Pro customers, but it names few Pro sites publicly.2,1
Company durability, 8.5: Equashield had revenue of 120 million euros in 2025 and 470 employees, and Nordic Capital has owned it since 2022.2
Ease of integration, 6.5: The Pro relies on Equashield's own closed transfer devices throughout, which fits pharmacies on that system but ties consumables to one supplier.1
Each criterion is defined on our methodology page.
Who uses EQUASHIELD Pro and what it's for
The buyer is a hospital oncology pharmacy that compounds hazardous drugs and wants automation with closed transfer protection for staff.1
EQUASHIELD Pro
Equashield says the Pro is the highest-throughput automated compounder on the market at up to 70 doses an hour, with a small footprint and built-in closed transfer safety.1
Pricing
Equashield sells the Pro by quote and does not list prices.1
Competitive landscape
| Company | Product | Pricing model | Deployment footprint | Where EQUASHIELD Pro wins or loses |
|---|---|---|---|---|
| EQUASHIELD Pro | Automated hazardous drug compounder using closed transfer devices1 | Not published; quote1 | Equashield sells on five continents2 | CSTD-based hazardous compounder; quote only; Equashield |
| ARxIUM | RIVA IV robot plus packagers, cabinets, and inventory software3 | Not published; consultation11 | More than 19 million RIVA doses4 | ARxIUM wins on one vendor for IV robots and wider pharmacy automation. EQUASHIELD Pro wins on closed transfer protection from start to finish. |
| KIRO Oncology | Two-arm hazardous drug compounder with gravimetric checks6 | Not published; quote6 | Part of the inclusiv IV compounding portfolio12 | KIRO Oncology wins on gravimetric checks and self-cleaning. EQUASHIELD Pro wins on closed transfer protection from start to finish. |
| Omnicell | IVX Station robot inside the IV Compounding Service9 | Not published; service model9 | Hospitals, clinics, and care settings8 | Omnicell wins on a managed IV compounding service. EQUASHIELD Pro wins on closed transfer protection from start to finish. |
| Loccioni APOTECAchemo | APOTECAchemo IV chemotherapy compounding robot10 | Not published10 | User community across the US, Europe, the Gulf, and Asia10 | Loccioni wins on an established chemo compounding user community. EQUASHIELD Pro wins on closed transfer protection from start to finish. |
Limits
No published prices.1
Uses Equashield's own closed transfer devices throughout.1
Few named deployments.2
What customers say
Where it helps
Closed transfer protection from start to finish.1
Where it falls short
Quote-only pricing.1
Company backing
Equashield, based in Tefen, Israel, had revenue of 120 million euros in 2025, above our full-review range, so this page is scoped to its EQUASHIELD Pro compounding robot.2
Sources
- Equashield, EQUASHIELD Pro automated compounding of hazardous drugs, accessed November 10, 2026
- Nordic Capital, Equashield portfolio company profile, accessed November 10, 2026
- ARxIUM, RIVA robotic IV automation and compounding systems, accessed November 10, 2026
- ARxIUM, News and events hub, accessed November 10, 2026
- ARxIUM, Our headquarters, accessed November 10, 2026
- Kiro Grifols, KIRO Oncology, accessed November 10, 2026
- Grifols, Grifols reports revenues of EUR 7,524m, up 7% (February 26, 2026), accessed November 10, 2026
- Omnicell, homepage, accessed November 10, 2026
- Omnicell, IV compounding, accessed November 10, 2026
- Loccioni, Apoteca Community, accessed November 10, 2026
- ARxIUM, homepage, accessed November 10, 2026
- Kiro Grifols, Robotic and other compounding devices, accessed November 10, 2026
- Omnicell, Fiscal year and fourth quarter 2025 financial results, accessed November 16, 2026

